KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Travere Therapeutics (TVTX) over the last 15 years, with Q3 2025 value amounting to $5.9 million.

  • Travere Therapeutics' Other Non-Current Liabilities fell 6360.51% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year decrease of 6360.51%. This contributed to the annual value of $6.8 million for FY2024, which is 3414.73% down from last year.
  • Per Travere Therapeutics' latest filing, its Other Non-Current Liabilities stood at $5.9 million for Q3 2025, which was down 6360.51% from $7.9 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Other Non-Current Liabilities peaked at $76.2 million during Q3 2022, and registered a low of $5.9 million during Q3 2025.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $16.6 million (2024), whereas its average is $35.6 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first soared by 22427.13% in 2021, then crashed by 8900.13% in 2023.
  • Quarter analysis of 5 years shows Travere Therapeutics' Other Non-Current Liabilities stood at $67.1 million in 2021, then tumbled by 86.01% to $9.4 million in 2022, then rose by 9.96% to $10.3 million in 2023, then plummeted by 34.15% to $6.8 million in 2024, then decreased by 12.77% to $5.9 million in 2025.
  • Its Other Non-Current Liabilities was $5.9 million in Q3 2025, compared to $7.9 million in Q2 2025 and $7.3 million in Q1 2025.